BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

NEXT STORY
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
PREV STORY
Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Argos Therapeutics to Participate in 2016 Cell & Gene Meeting on the Mesa

DURHAM, N.C., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an ...

author_avatar
NASDAQ Market News

Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights

author_avatar
NASDAQ Market News

Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program

author_avatar
NASDAQ Market News